Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Andy Povey - Escalations and Key Accounts manager ... good to finally see a sales role in the team... looks like some focus on B2B sales too...
“ The tube is then placed into a simple heat block or water bath to keep the sample warm throughout the chemical reaction, which takes 30 minutes or less to provide a colorimetric reading based on detection of the presence of the virus.”
So yeah, we’ve all got heat blocks and water baths lying around... still too complex.
The UT last night was about 5/6p above the SP at 136... the late trading was 130...
So this drop isn’t as bad as it looks. So it’s not a crazy drop on open.
Hold steady people.
Big Al got thesaurus out for next RNS...
Place your bets on:
Soon - Evens
Promptly - 2/1
Quickly - 3/1
Rapidly - 6/1
Forthwith - 6/1
Shortly - 10/1
Speedily - 16/1
Around the Corner - 100/1
Or if you’re after a bit of deramping action:
Never - 3/1
We’ve Fecked it up - 20/1
We shouldn’t have sent all our IP on email to NYCT, sorry shareholders - 250/1
Interesting...
Could well be!
I read this as we can validate quickly, IF we have access to other sources of samples, that are not just Condor.
If those collaborations can be done quickly then fine, but this suggests we need more before we get the news we want on LFT.
Sounds like more news needed on that front.
Does anyone else read this paragraph to mean, Avacta will need other collaborations to get the sample numbers at the level to validate the lateral flow test “quickly”? So this Condor one won’t be enough?
“This, combined with other collaborations that we are putting in place, will provide us with access to a sufficient number of COVID-19 patient samples to allow us to quickly clinically validate the saliva rapid test.“
Whilst I’m as frustrated as the next person at the lack of news, here’s the evidence of rushing something and getting it wrong! I don’t want to hear Avacta ever having failed being spoken about in The Commons.
It’s good but it’s still “antigens in nasal swabs”... so still not an ideal way to test if saliva can be shown to be as accurate (or better!)
Just to clear this one up... you can stop Google crawling yourself website, which in turns means your site doesn’t turn up in the natural rankings.
This can be used (and is) when developing a new site and you have holding pages in place. My guess is this is exactly what is happening here, with development work going on behind the scenes.
The existing website/web pages are very simple and I believe are just a stop gap. There are none of the obvious e-commerce traits I would expect to see, given the calibre of the boohoo team and their expertise.
But they needed something or folks on BBs would be complaining the “distributor doesn’t even have a website”, well that and gather leads of interested parties!
What are people’s views on the late trades?
LSE looks like lots of big buys going on all day, but unsure of spread etc.
Someone with L2... Are they buys or sells?
I think so, first line an indicator “ announces in response to substantial institutional interest”
Anyone seen these? They were supposed to be out this week, were they not?
And before anyone says DYOR etc, I have and I’m invested, I just interested in his perspective.
Clues in the name for where this product will be focussed...
Medusa19
MED (assume short for medical) USA (Assume the country). 19 (assume covid related)
This is very astute by our BOD.
Boohoo founders know how to go to market. They’ve done it from nothing.
They can do it worldwide
Sales and marketing is a skill set in its own right. Avacta don’t have it (they do have lots of others)
The other thing I think people are missing...
MED. USA. 19.
So where do you think they’ll be targeting first!
@SC - the partnership with Adeptrix was agreed to do just that... use Avacta’s technology in existing technology, already available in hospitals
So we’re seeing Avacta tackle both the existing equipment market, and open up new markets too.
Surprised to read (from presentation News flow section) that Antigens are yet to be shipped to partners.
Given the update RNS a few weeks ago about progress and being ahead of schedule, I’d have thought that would be done by now.
https://www.*************.net/ceo-qa-with-alistair-smith-at-avacta-group-lonavct/
CEO Q&A with Alistair Smith at Avacta Group (LON:AVCT)
Avacta Group plc (LON:AVCT) Chief Executive Officer Alastair Smith caught up with ************* for an exclusive interview to discuss generating over 50 affimer reagents in only 4 weeks for their partnership with Cytiva.
Q1: Avacta Group announced earlier this week that its partnership with Cytiva was ahead of schedule, can you remind us what that partnership involves?
A1: We’re collaborating with Cytiva, which was formally GE Healthcare Life Sciences until they were acquired by Danaher a few weeks ago, to develop a rapid point of care test for the coronavirus antigen. So, that’s a test that tells you whether you’ve got the infection right now or not, not that you’ve had it in the past, it’s not an antibody test but an antigen test.
That test is going to be a rapid test, it’ll take a few minutes rather like a pregnancy test strip with a visible readout so one blue line, two blue lines, and it’ll use saliva as the sample. It’ll be for professional use and consumer self-testing.
Q2: Can you explain for us the detail behind the announcement earlier this week?
A2: The first part of the collaboration with Cytiva for us to produce affimers that could detect the virus and the announcement a couple of days ago was to update the market that we had successfully achieve that and done it in only 4 weeks which, even by our standards, is extremely quick.
So, we’ve now generated a large number of affimer reagents, more than 50, that bind to the spikes on the outside of the virus, we’ve all seen pictures of the virus, the affimers detect those spikes particular to the coronavirus.
Those can now be used in a point of care test and with other types of diagnostic testing as well.
Q3: Looking forward, what are the next steps now in the partnership and more widely for Avacta Group?
A3: We’re now identifying the best affimer reagents from those 50 or so that we’ve generated and we’re going to provide those to Cytiva very soon, probably next week, so they can begin developing that rapid test strip diagnostic format.
We have retained all of the commercial rights for the affimers and the testing. So, we’re going to continue our ongoing discussions wi9th other diagnostic companies with a view to establishing other partnerships to develop rapid tests, like the test strips, but also other forms of diagnostic test that can add to the overall testing capacity to fight this infection.
27-Apr-20 13:05:51 100.00 685 Buy* 685.00